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OriginalBasicScienceçGeneralTransgenic Expression of Human Thrombomodulin
Inhibits HMGB1-Induced Porcine Aortic
Endothelial Cell Activation
Anjan K. Bongoni, PhD,1 Nikolai Klymiuk, PhD,2 Eckhard Wolf, DVM,2 David Ayares, PhD,3 Robert Rieben, PhD,4
and Peter J. Cowan, PhD1,5Background. Transgenic expression of human thrombomodulin (hTBM), which has the potential to solve the problem of coag-
ulation dysregulation in pig-to-primate xenotransplantation, may have additional benefits by neutralizing the proinflammatory cyto-
kine high-mobility group box 1 (HMGB1). The aim of this study was to investigate HMGB1-mediated effects on porcine aortic
endothelial cells (PAEC) from wild-type (WT) and hTBM transgenic pigs.Methods. Porcine aortic endothelial cells were treated
with HMGB1, human (h)TNFα or lipopolysaccharide (LPS). Procoagulant and proinflammatory responses were assessed bymea-
suring expression of cell surface markers (adhesion molecules, fibrinogen-like protein 2, plasminogen activator inhibitor (PAI)-1),
secretion of porcine cytokines and chemokines (HMGB1, TNFα, IL-8, monocyte chemotactic protein-1), and formation of PAI-
1/tissue plasminogen activator complexes. Thrombin-mediated degradation of HMGB1 in the presence of PAEC was examined
byWestern blot and functional assay.Results.High-mobility group box 1 potently activatedWTPAEC, increasing the expression
of E-selectin, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, fibrinogen-like protein 2, and PAI-1, the secre-
tion of TNFα, IL-8, and monocyte chemotactic protein-1 and the formation of PAI-1/tissue plasminogen activator complexes. Hu-
man TNFα- or LPS-induced activation of WT PAEC was inhibited by treatment with rabbit anti-HMGB1 antibody. Transgenic
expression of hTBM significantly reduced the activation of PAEC by HMGB1 or hTNFα, and significantly enhanced thrombin-
induced HMGB1 cleavage. Chemically induced shedding of the lectin-like domain of TBM resulted in significantly increased
HMGB1-induced PAEC activation.Conclusions.High-mobility group box 1 exerts powerful proinflammatory and procoagulant
effects on WT PAEC, and appears to be an important downstream mediator for the actions of hTNFα and LPS. Human
thrombomodulin transgenic PAECs are less sensitive to activation by either HMGB1 or hTNFα, an effect that appears to be depen-
dent on the lectin-like domain of TBM.
(Transplantation 2016;100: 1871–1879)P ig-to-human xenotransplantation offers a potential so-lution to the chronic shortage of human donor organs.
However, porcine xenografts induce a powerful immune re-
sponse, inwhich coagulationand inflammationplay an important
role. Genetically modified pigs expressing human complement
regulatory proteins on the α1,3-galactosyltransferase gene knock-
out (GTKO) background have been developed to address the
initial barrier of hyperacute rejection. However, coagulation
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to longer term xenograft survival.1
The thrombomodulin (TBM)/protein C pathway is a criti-
cal regulator of coagulation and inflammation within the mi-
crovasculature. Thrombomodulin is an integral endothelial
membrane protein that alters the specificity of thrombin from
procoagulant and proinflammatory substrates to protein C,
which in its activated form inhibits coagulation and inflam-
mation. However, this key regulatory mechanism is compro-
mised in xenotransplantation because pig TBMbinds humanhTBM and galactosyltransferase gene-knockout/hCD46/hTBM pigs. D.A. provided
primary cells from hCD46 transgenic pigs for nuclear transfer experiments. R.R. pro-
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1872 Transplantation ■ September 2016 ■ Volume 100 ■ Number 9 www.transplantjournal.comthrombin but is a poor cofactor for the activation of human
protein C, with only less than 10% of the activity of human
TBM (hTBM).2 Transgenic expression of hTBM is a promis-
ing approach to overcome this molecular incompatibility.
Transgenic hTBM on porcine aortic endothelial cells (PAEC)
prolonged the clotting time of human blood in vitro.3 In vivo,
hTBM expression on cardiac xenografts was associated with
a delay in the development of thrombotic microangiopathy
and/or consumptive coagulopathy.4
In addition to its anticoagulant properties, TBM also attenu-
ates inflammation through activated protein C-dependent and
-independent mechanisms. The lectin-like domain of TBM
inhibits complement activation andneutralizes endotoxin.5
It also sequesters the “danger signal” high-mobility group
box 1 (HMGB1) and facilitates its cleavage by thrombin.
High-mobility group box 1 is a highly conserved protein
present in the nucleus and cytoplasm of almost all cell types
(reviewed in Ito et al6). High-mobility group box 1 serves a
dual function as an intracellular DNA-binding protein,
maintaining nucleosome structure and regulation of gene
transcription, and as an extracellular signal of tissue dam-
age. High-mobility group box 1 is passively released from
necrotic or damaged cells or actively secreted by inflamma-
tory cells, including activated monocytes, macrophages,
neutrophils, and endothelial cells.7,8 ExtracellularHMGB1
initiates potent innate immune responses by promoting che-
motactic cell interactions, cytokine production, T cell activa-
tion, dendritic cell maturation, and coagulation activation,
via its binding to pattern recognition receptors including
the receptor for advanced glycation end-products and Toll-
like receptors 2 (TLR2) and 4 (TLR4).8,9
Although initial findings demonstrated HMGB1 as a late
mediator of sepsis,10 recent studies indicate that HMGB1
also plays a pivotal role in the pathogenesis of a range of
inflammatory states11 including transplant rejection.12
Anti-HMGB1 treatment can significantly prolong cardiac
xenograft survival in a rat-to-mouse model.13 However,
HMGB1-mediated activation of porcine endothelial cells
has not been explored, and the protective effect of hTBM
against HMGB1's actions in this setting has not been exam-
ined. We therefore aimed to test HMGB1-mediated proin-
flammatory and procoagulant effects on PAEC and to
assess the capacity of transgenic expression of hTBM on
PAEC to neutralize HMGB1.
MATERIALS AND METHODS
Cell Culture
Porcine aortic endothelial cells were isolated from wild-
type (WT), hTBM- or GTKO.hCD46. hTBM transgenic pig
aorta as described previously.3,14 Porcine aortic endothelial
cells were used between passages 2 and 8 in all experiments.
Cell Enzyme Linked Immunosorbent Assay
Confluent WT, hTBM, and GTKO.hCD46. hTBM PAEC
grown in 96-well plates were treated with HMGB1
(HMGBiotech, Milan, Italy; 50-200 ng/mL) or human (h)
TNFα (R&D Systems,Minneapolis,MN; 10 ng/mL) or lipo-
polysaccharide (LPS) from Escherichia coli 026: B6 (Sigma-
Aldrich, Castle Hill, Australia; 100 ng/mL) in the presence
or absence of rabbit anti-HMGB1 antibody (Sigma-Aldrich)
at 37°C for 4 to 24 hours. In some experiments, PAEC wereCopyright © 2016 Wolters Kluwerpretreated with either human thrombin (Merck Millipore,
Bayswater,Australia;5U/mLfor60minutes)or lysophosphatidic
acid (LPA) (10 μM for 10 minutes). After fixation with 3.7%
formalin for 15 minutes and blocking with phosphate-
buffered saline-3% bovine serum albumin for 30 minutes at
room temperature, cells were incubated with mouse anti-
human E-selectin (fluorescein isothiocyanate [FITC] labeled;
AbD Serotec, Oxford, UK), mouse antipig vascular cell adhe-
sion molecule (VCAM)-1 (10.2C7, generously provided by
D.O. Haskard [Department of Immunology, Royal Post-
graduate Medical School, Hammersmith Hospital, London,
UK]), mouse antihuman intercellular adhesion molecule
(ICAM)-1 (FITC; AbD Serotec), rabbit antihuman fibrino-
gen like-2 (FGL2, Aviva Systems Biology, San Diego, CA),
mouse antihuman plasminogen activator inhibitor-1 (PAI-1)
(Hycult Biotech, Uden, The Netherlands), and rabbit anti-
human tissue plasminogen activator (tPA) (Molecular Inno-
vations, Novi, MI). Subsequently, biotin-conjugated rabbit
anti-mouse IgG (Dako, Braeside, Australia) or goat anti-
rabbit IgG (Dako) and alkaline phosphatase conjugated rabbit
anti-FITC(Abcam,Melbourne,Australia)oralkalinephospha-
tase (AP)-streptavidin (GE Healthcare, Parramatta, Australia)
were used. Finally, p-nitrophenyl phosphate substrate (Sigma-
Aldrich) was added and color development was quantified
using a FLUOstar Omega microplate reader.Enzyme Linked Immunosorbent Assay
Fluid phase PAI-1/tPA complex was measured as an anti-
fibrinolytic marker using mouse antihuman PAI-1 (Hycult
Biotech) and biotinylated rabbit antihuman tPA (Molecular
Innovations) antibodies. High-mobility group box 1 in culture
supernatant was detected using an in-house developed enzyme
linked immunosorbent assay (ELISA) with mouse antihuman
HMGB1 and horseradish peroxidase-conjugated rabbit anti-
human HMGB1 (Abcam) antibodies. Full-length HMGB1
protein (Abcam) was used as a standard. Streptavidin-AP and
the appropriate substrate were used for color development.
Production of porcine cytokines (TNFα, IL-8, andmonocyte
chemotactic protein [MCP]-1) by PAECwas measured in cell
culture supernatants using specific porcine DuoSet kits (TNFα
and IL-8, R&D Systems) and MCP-1 ELISA kit (PeproTech,
RockyHill, NJ) according tomanufacturer's protocol.Western Blot
Porcine aortic endothelial cells were pretreated with
thrombin (Merck Millipore) for 30 minutes, followed by
HMGB1 treatment for 30 minutes. Cells were lysed in
radioimmunoprecipitation buffer (Sigma-Aldrich) with prote-
ase inhibitor cocktail (Sigma-Aldrich). Samples were electro-
phoresed on 4% to 20% mini-Protean TGX precast gels
(Bio-Rad, Gladesville, Australia) and analyzed by Western
blot. Membranes were blocked with 50% Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE) and stained with
anti-HMGB1 (Abcam). Thereafter, membranes were probed
with the appropriate secondary antibodies conjugated to
IRDye 680CW (LI-COR Biosciences). Membranes were
scanned with a LI-COR near-infrared Odyssey scanner (LI-
COR Biosciences). Quantification of fluorescence intensity as
raw integrated density was performed using Image J software,
version 10.2 (National Institutes of Health). Health, Inc. All rights reserved.
FIGURE 1. Effect of transgenic expression of hTBM on the NHS-, hTNFα- or LPS-induced release of HMGB1 from PAEC. Confluent WT,
hTBM, and GTKO.hCD46.hTBM PAEC grown in 12-well plates were stimulated with (A) NHS (1:10) or (B) hTNFα (10 ng/mL) or (C) LPS
(100 ng/mL) for 16 hours, and the release of HMGB1 in cell culture supernatants was measured by ELISA. Statistical analysis was done by
1-way ANOVA testing with Bonferroni correction (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). All results are shown as mean ± SD
of 3 independent experiments. ANOVA, analysis of variance.
© 2016 Wolters Kluwer Bongoni et al 1873Immunofluorescence Staining
Wild-type and hTBM PAEC grown on 8-well Lab-Tek
chamber slides (Milian, Geneva, Switzerland) were pretreated
with LPA (10 μM for 10 minutes) and incubated with
HMGB1 or hTNFα for 16 hours. After this, cells were incu-
bated with mouse antihuman TBM (clone D-3; Santa Cruz
Biotechnology, Geneva, Switzerland; and clone 141C01;
Lifespan Biosciences, Seattle, WA) and rat anti-pig CD31
(R&D Systems) for 60minutes. Thereafter, cells were exposed
to goat anti-rat IgG-Alexa594, and goat anti-mouse IgG-
Alexa488 (Molecular Probes). Nuclei were stained using 4′,6-
diamidino-2-phenylindole (DAPI, Boehringer Ingelheim,
North Ryde, Australia). The slides were analyzed using a
Nikon A1R confocal microscope.
Statistical Analysis
Data are shown as mean ± standard deviation. Statistical
analysis was performed using GraphPad Prism 6 (GraphPad
Software, San Diego, CA). Significance was tested using Stu-
dent t test and 1-way analysis of variance with Bonferroni
correction (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001,
****P ≤ 0.0001).
RESULTS
Human Serum, hTNFa, and LPS Induce the Release of
HMGB1 From PAEC
Wild type, hTBM or GTKO.hCD46.hTBM PAEC were
stimulated for 16 hours with normal human serum (NHS,
1:10), hTNFα (10 ng/mL) or LPS (100 ng/mL), and analyzed
for HMGB1 release in culture supernatants. As shown in
Figure 1, a low amount of HMGB1 was detected in superna-
tants of all untreated PAEC (1.3 ± 0.3 to 2.0 ± 0.3 ng/mL).
Treatment of WT PAEC with NHS, hTNFα, or LPS signifi-
cantly increased HMGB1 levels, by 5.5-, 6-, and 7-fold, re-
spectively. High-mobility group box 1 levels were also
increased by each of the treatments of hTBM PAEC, and by
hTNFα or LPS treatment of GTKO.hCD46.hTBM PAEC.
However, the rise inHMGB1 under all conditions was signif-
icantly blunted in the transgenic cells compared with WTCopyright © 2016 Wolters Kluwer Hcells, suggesting that elevated TBM expression increased se-
questration of HMGB1 and/or reduced activation of the
PAEC. Interestingly, HMGB1 was not significantly increased
by NHS treatment of GTKO.hCD46.hTBM PAEC, consis-
tent with reduced xenoantibody binding, complement activa-
tion, and cellular activation.
Anti-HMGB1 Treatment Inhibits hTNFa- and
LPS-Induced Activation of WT PAEC
To investigate the effects of HMGB1 inhibition on PAEC
activation,WT PAECwere treated for 16 hours with hTNFα
or LPS in the presence or absence of rabbit antihuman
HMGB1 antibody (2 or 5 μg/mL). Human TNFα and LPS
significantly induced expression of the adhesion molecules
E-selectin and VCAM-1, markers of endothelial cell activa-
tion, on WT PAEC (Figures 2A-B). However, anti-HMGB1
antibody treatment significantly reduced the upregulation
of both markers, in a dose-dependent manner. Furthermore,
anti-HMGB1 treatment significantly reduced the hTNFα-
and LPS-mediated secretion of porcine TNFα, IL-8 and
MCP-1 (Figures 2C-E). These results suggest that HMGB1
release triggered by proinflammatory mediators is a central
downstream amplifier of PAEC activation.
Transgenic hTBM Inhibits HMGB1-Induced
Activation of PAEC
High-mobility group box 1 increased the expression of E-
selectin, VCAM-1, and ICAM-1 on WT PAEC in a dose-
and time-dependent manner. Cotreatment with hTNFα and
HMGB1 caused a further increase in activation over that ob-
served with hTNFα treatment alone (Figure S1, SDC, http://
links.lww.com/TP/B262).
Incubationof confluentWTPAECwithHMGB1 (100ng/mL,
16hours) or hTNFα (10 ng/mL, positive control) resulted in sig-
nificantly increased expression of E-selectin, VCAM-1, and
ICAM-1 as compared with untreated PAEC. Stimulation of
hTBM PAEC under the same conditions increased the expres-
sion of E-selectin and ICAM-1, but not VCAM-1. However,
the rise in expression of these endothelial cell activationmarkersealth, Inc. All rights reserved.
FIGURE 2. Effect of anti-HMGB1 antibody treatment on the hTNFα- and LPS-induced activation of WT PAEC. Confluent WT PAEC were
treatedwith hTNFα (10 ng/mL) or LPS (100 ng/mL) in the presence of rabbit anti-HMGB1antibody (0-5μg/mL) for 16 hours and the cell surface
expression of (A) E-selectin and (E) VCAM-1 was measured by a cell-based ELISA. (C-E) After 16 hours of treatment with hTNFα or LPS in the
presence of anti-HMGB1, cell culture supernatants of WT PAEC were analyzed for the release of porcine proinflammatory cytokines (C) TNFα
(D) IL-8 and (E) MCP-1 by using commercial ELISA kits. Statistical analysis was done by 1-way ANOVA testing with Bonferroni correction
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). All results are shown as mean ± SD of 3 independent experiments.
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PAEC (Figures 3A-C). No additional protection fromHMGB1-
or hTNFα-induced upregulation of E-selectin, VCAM-1, andFIGURE 3. Effect of hTBM on the HMGB1- or hTNFα-mediated expres
were treated with HMGB1 (100 ng/mL) or hTNFα (10 ng/mL, positive c
(B) ICAM-1 and (C) VCAM-1 was measured by cell ELISA. D-F, Significa
rection (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Data are m
Copyright © 2016 Wolters KluwerICAM-1 expressionwas observedwhenGTKO.hCD46.hTBM
PAECwere used instead of hTBM-only PAEC (Figure S2, SDC,
http://links.lww.com/TP/B262).sion of cell adhesion molecules in PAEC. A-C, WTand hTBM PAEC
ontrol) for 16 hours, and the cell surface expression of (A) E-selectin,
nce was tested using 1-way analysis of variance with Bonferroni cor-
ean ± SD of 3 independent experiments.
 Health, Inc. All rights reserved.
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Cytokines by PAEC
To further examine the role of HMGB1 in proinflamma-
tory cytokine release, WT and hTBM PAEC were incubated
with HMGB1 or hTNFα as positive control, and the levels
of secreted proinflammatory porcine cytokines TNFα, IL-8,
andMCP-1 were quantified by ELISA. Secretion of these cy-
tokines was upregulated in both WT and hTBM PAEC.
However, cytokine secretion by hTBM PAEC was signifi-
cantly lower than by WT PAEC (Figure 4).
HMGB1 Transforms PAEC to a Procoagulant and
Antifibrinolytic Phenotype
Wild-type and hTBM PAECwere stimulated with HMGB1
or hTNFα and expression of FGL2 and PAI-1 as procoagulant
and antifibrinolytic markers, respectively, was evaluated by
cell ELISA. Both FGL2 and PAI-1 were significantly upregu-
lated on WT PAEC, whereas only the increase of PAI-1 was
significant on hTBM PAEC (Figures 5A-B). For both surface
markers, upregulation was reduced on hTBM as compared
to WT PAEC.
In addition, the formation of PAI-1/tPA complexes was
measured in culture supernatants obtained from WT and
hTBM PAEC incubated with HMGB1 or hTNFα. Baseline
values of PAI-1/tPA complexes were minimal and not signifi-
cantly different between WTand hTBM PAEC samples. For-
mation of PAI-1/tPA complexes significantly increased after
stimulation ofWTbut not hTBMPAEC, and PAI-1/tPA com-
plex formation was reduced in hTBM as compared with WT
PAEC (Figure 5C).
Transgenic hTBM Accelerates the Cleavage of
HMGB1 by Thrombin
To examine cleavage of HMGB1 by human thrombin
bound to TBM, WT and hTBM PAEC were incubated with
HMGB1 (10 μg/mL for 30 minutes) with or without pre-
treatment of the cells with human thrombin (5 U/mL for
30 minutes). Western blot/Image J analysis of supernatants
showed that the presence of hTBM significantly enhanced
thrombin-mediated cleavage of HMGB1 as compared to
WT PAEC (Figures 6A-B).
Next, we examined the functional consequences of HMGB1
degradation by thrombin in the presence of hTBM. Wild-
type and hTBM PAEC were stimulated with HMGB1FIGURE 4. Effect of hTBM on the HMGB1- or hTNFα-mediated secret
tants of WTand hTBM PAEC treated with HMGB1 (100 ng/mL) or hTNFα
inflammatory cytokines (D) TNFα, (E) IL-8 and (F) MCP-1 by ELISA. Da
experiments. Significance was tested using 1-way ANOVA with Bonferro
Copyright © 2016 Wolters Kluwer H(100 ng/mL) or hTNFα (10 ng/mL) for 16 hours with or with-
out pretreatment of the cells with human thrombin (5 U/mL)
for 60 minutes. Expression of E-selectin and VCAM-1 was
then measured by cell ELISA. Pretreatment of the cells with
thrombin resulted in significantly downregulated expression
of E-selectin and VCAM-1. In addition, the presence of the
hTBM transgene led to a significant decrease of E-selectin
and VCAM-1 expression as compared with WT PAEC
(Figures 6C-F).
The Lectin-like Domain of Thrombomodulin Is
Important for Inhibition of HMGB1-Induced
Inflammation
To study the role of TBM's lectin-like domain in anti-
inflammatory responses, hTBM PAEC were treated with
10 μMLPA for 10 minutes. Lysophosphatidic acid is known
to cleave the lectin-like domain fromTBM, and this was con-
firmed using the monoclonal anti-TBM antibody D-3, with
specificity for the lectin-like domain. Antibody D-3 and clone
141C01, which is specific for the epidermal growth factor
(EGF)-like domain of TBM, were used for immunofluores-
cence staining of LPA-treated PAEC. Complete absence of
D-3 antibody binding indicated cleavage of the lectin-like do-
main of hTBM by LPA, whereas no difference for EGF-like
domain staining with the 141C01 antibody was observed.
In addition, expression of CD31, an endothelial cell marker,
was not influenced by LPA treatment (Figures 7A-B).
To verify whether cleavage of the lectin-like domain influ-
ences the anti-inflammatory effect of TBM via binding of
HMGB1, WT and hTBM PAEC were treated with HMGB1
or hTNFα for 16 hours with or without pretreating the cells
with 5 μMLPA for 10minutes. Cleavage of the lectin-like do-
main by LPA resulted in significantly increased HMGB1- or
hTNFα-induced expression of E-selectin and VCAM-1 as
compared to PAEC without LPA treatment (Figures 7C-F).DISCUSSION
In this study, we have demonstrated that HMGB1 exerts
potent proinflammatory and procoagulant effects on WT
PAEC, and that hTBM-expressing PAEC are less sensitive
to activation by either HMGB1 or hTNFα. Expression of
hTBM on PAEC inhibits hTNFα- or LPS-mediated secretion
of HMGB1 and attenuates HMGB1-mediated responses,ion of proinflammatory cytokines in PAEC. A-C, Cell culture superna-
(10 ng/mL) for 16 hours were measured for the levels of porcine pro-
te are mean values ± standard deviations of at least 3 independent
ni correction (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
ealth, Inc. All rights reserved.
FIGURE 5. Inhibition of HMGB1- or hTNFα-induced procoagulant and antifibrinolytic activities in PAEC by transgenic expression of hTBM. A-
B,WTand hTBMPAECwere treated with HMGB1 (100 ng/mL) or hTNFα (10 ng/mL, positive control) for 16 hours, and the cell surface expres-
sion of procoagulant FGL2 and (B) antifibrinolytic PAI-1 was measured by cell ELISA. C, Cell culture supernatants of PAEC treated as above
were collected and processed for the levels of fluid-phase antifibrinolytic marker, PAI-1/tPA complex formation by ELISA as described in Ma-
terials and methods. Statistical analysis was carried out by 1-way ANOVA testing with Bonferroni correction. Data are mean ± SD,
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n = 3 independent experiments.
1876 Transplantation ■ September 2016 ■ Volume 100 ■ Number 9 www.transplantjournal.compresumably by sequestering HMGB1 and thus preventing
binding to receptor for advanced glycation end-products and
TLR2 and TLR4. The protection against the effects of
LPS may have also been mediated in part by neutralization
of the endotoxin by the lectin-like domain of TBM.5
High-mobility group box 1 has 99% sequence identity
across mammalian species and is known to be involved in in-
flammatory responses. To test whether HMGB1 is secreted
by PAEC and participates in endothelial activation, we stim-
ulated WT PAEC with NHS or hTNFα or LPS. We showed
that HMGB1 was secreted after stimulation of WT PAEC.
It was shown recently that TBM plays an important role in
suppressing inflammation, independent of its anticoagulant
activity.15 In line with this finding, hTBM transgenic PAEC
secreted less HMGB1 than WT PAEC upon stimulation by
NHS, hTNFα, or LPS. We also showed that HMGB1 stimu-
lates WT PAEC to express the adhesion molecules E-selectin,
VCAM-1, and ICAM-1 and to secrete the proinflammatory
cytokines TNFα, IL-8, and MCP-1. These findings indicate
that HMGB1 activates porcine endothelial cells and that ex-
pression of hTBM can prevent this. High-mobility group
box 1 also induced PAEC to express the procoagulant
molecule FGL2 and to secrete the antifibrinolytic mediator
PAI-1, indicating the induction of a procoagulant and an
antifibrinolytic state of the endothelium. The latter was fur-
ther supported by the increased formation of PAI-1/tPA com-
plexes, which are fluid-phase antifibrinolytic markers. This
transition of PAEC to a procoagulant and antifibrinolytic
state, which triggers thrombotic microangiopathy in pig-to-
primate xenotransplantation,1 was significantly inhibited
by transgenic hTBM expression. Transgenic hTBM on the
surface of endothelial cells binds and prevents dissemination
of HMGB1, thereby reducing the engagement of HMGB1
with its proinflammatory receptors.16 Therefore, neutraliza-
tion of HMGB1 by overexpression of hTBM represents a
possible strategy to control HMGB1-mediated PAEC activa-
tion, preventing the establishment of a procoagulant and
antifibrinolytic state of the porcine endothelium during xeno-
graft injury.
Recombinant soluble hTBM is approved for clinical
treatment of disseminated intravascular coagulation inCopyright © 2016 Wolters KluwerJapan, and has been shown to inhibit HMGB1 in several
small animal models. Treatment with soluble hTBM might
therefore be considered as an alternative to transgenic ex-
pression. However, soluble TBM appears to have less po-
tent anti-inflammatory effects on PAEC than membrane-
bound TBM.17 Furthermore, overexpression of hTBM on
the xenograft vascular surface restricts anticoagulation
and anti-inflammatory functions to where they are needed
most. We therefore believe that, in the setting of xenotrans-
plantation, the transgenic approach to boost TBM activity
has considerable advantages over systemic treatment with
soluble TBM.
We have previously reported that the lectin-like domains
of porcine and human TBM share 71.4% amino acid iden-
tity.2 The lectin-like domain of TBM is not involved in
thrombin binding and has no known role in the activation
of protein C.15 However, recent studies revealed that the
lectin-like domain directly modulates inflammatory re-
sponses by scavenging HMGB1, which can then be cleaved
and inactivated by TBM-bound thrombin.16,18 Our results
with WT PAEC indicate that the lectin-like domain in por-
cine TBM can bind HMGB1 and promote, at least to some
extent, its cleavage by human thrombin, and that overex-
pression of hTBM significantly accelerates this process. Al-
though we were unable to directly compare the surface
levels of porcine and human TBM due to the unavailability
of an appropriate antibody, our results suggest that themore
effective neutralization of HMGB1 by the transgenic PAEC
is most likely due to increased expression of (total) TBM.
Furthermore, hTBM PAEC showed reduced surface expres-
sion of E-selectin and VCAM-1 when pretreated with
thrombin and then incubated with HMGB1. These findings
are consistent with previous results, showing that thrombin-
cleaved HMGB1 has significantly decreased proinflamma-
tory activities.18
Lysophosphatidic acid, a bioactive lipid mediator present
in biological fluids during endothelial damage or injury, en-
hances shedding of the lectin-like domain of TBM from hu-
man vascular endothelial cells.19 We treated hTBM PAEC
with LPA and showed that LPA specifically cleaved the
lectin-like domain of TBM, whereas its EGF-like domain Health, Inc. All rights reserved.
FIGURE 6. Transgenic hTBM enhanced thrombin-mediated proteolytic cleavage of HMGB1 to a less potent stimulus. A, Schematic represen-
tation of TBM's anti-inflammatory properties by sequestration and thrombin-mediated degradation of HMGB1. B, Western blot analysis of
HMGB1 degradation. WT and hTBM PAEC were pretreated with human thrombin (5 U/mL) for 30 minutes before incubation with HMGB1
(10 μg/mL) for 30 minutes. Supernatants were subjected to SDS-PAGE followed by immunoblotting. One representative of 3 independent ex-
periments is shown. After thrombin treatment for 60minutes, (C and E) WTand (D and F) hTBM PAECwere stimulated with HMGB1 (100 ng/mL)
or hTNFα (10 ng/mL) for 16 hours, and the cell surface expression of (C-D) E-selectin and (E-F) VCAM-1 was measured by cell ELISA. Shown
are mean values ± standard deviations of at least 3 independent experiments. Significance was tested using 1-way ANOVA with Bonferroni
correction (*P < 0.05, **P < 0.01, ***P < 0.001).
© 2016 Wolters Kluwer Bongoni et al 1877stayed intact. Lysophosphatidic acid–induced TBM lectin-
like domain shedding resulted in a significant enhancement
of HMGB1- or hTNFα-induced E-selectin and VCAM-1 ex-
pression, demonstrating the anti-inflammatory function of
the lectin-like domain. Increased TBM expression on the
transgenic PAEC reduced activation by HMGB1 or hTNFαCopyright © 2016 Wolters Kluwer Hcompared with WT PAEC, and this protective effect was lost
with LPA pretreatment.We conclude from these observations
that the lectin-like domain of TBM indeed plays a role in reg-
ulating the proinflammatory action of HMGB1 on endothe-
lial cells, which is further boosted by overexpression of
hTBM on the transgenic PAEC.ealth, Inc. All rights reserved.
FIGURE 7. The lectin-like domain of hTBM provides protection against HMGB1- or hTNFα-induced PAEC activation. A, Schematic represen-
tation of LPA stimulated shedding of the lectin-like domain of hTBM. B, LPA-induced shedding of the lectin-like domain of TBM.Wild-type and
hTBM PAEC were treated with 10 μM LPA for 10 minutes, and analysed by immunofluorescence staining/confocal microscopy with an anti-
lectin-like domain (clone D-3) or anti-EGF-like domain (clone 141C01) of the hTBM antibody and a rat anti-porcine CD31 antibody. Scale
bar, 50 μm. C-F, Effect of LPA-mediated shedding of the lectin-like domain of hTBM on HMGB1- or hTNFα-induced PAEC activation. Wild-
type and hTBM PAEC were pretreated with LPA (10 μM) for 10 minutes before stimulation with HMGB1 (100 ng/mL) or hTNFα (10 ng/mL)
for 16 hours, and analyzed for the expression of adhesion molecules (C and E) E-selectin and (D and F) VCAM-1 by a cell-based ELISA. Sta-
tistical analysis was carried out by 1-way ANOVA testing with Bonferroni correction. Data are mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001; n = 3 independent experiments.
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© 2016 Wolters Kluwer Bongoni et al 1879In conclusion, HMGB1 has profound proinflammatory,
procoagulant and antifibrinolytic effects on endothelial cells.
It upregulates the expression of adhesion molecules and
transforms the endothelial cell surface to a procoagulant
and antifibrinolytic state by expression of FGL2 and PAI-1.
Transgenic expression of hTBMon PAEC limits these changes
by binding HMGB1 and promoting its cleavage by thrombin.
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